Your browser doesn't support javascript.
loading
Should the sex of the fetus be considered when administering antenatal corticosteroids to preterm fetuses?
Seker, Erdal; Kraja, Elvis; Çakir, Maide Selin; Köstekçi, Yasemin Ezgi; Obut, Mehmet; Okulu, Emel; Erdeve, Ömer; Atasay, Fatma Begüm; Arsan, Saadet; Koç, Acar.
Afiliación
  • Seker E; Department of Obstetrics and Gynecology, Osmaniye State Hospital, Osmaniye, Turkey.
  • Kraja E; Department of Neonatology, Ankara University School of Medicine, Ankara, Turkey.
  • Çakir MS; Department of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, Turkey.
  • Köstekçi YE; Department of Neonatology, Ankara University School of Medicine, Ankara, Turkey.
  • Obut M; Department of Obstetrics and Gynecology, Gazi Yasargil Education and Training Hospital, Diyarbakir, Turkey.
  • Okulu E; Department of Neonatology, Ankara University School of Medicine, Ankara, Turkey.
  • Erdeve Ö; Department of Neonatology, Ankara University School of Medicine, Ankara, Turkey.
  • Atasay FB; Department of Neonatology, Ankara University School of Medicine, Ankara, Turkey.
  • Arsan S; Department of Neonatology, Ankara University School of Medicine, Ankara, Turkey.
  • Koç A; Department of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, Turkey.
J Obstet Gynaecol Res ; 2024 Aug 26.
Article en En | MEDLINE | ID: mdl-39187973
ABSTRACT

AIM:

We aimed to determine whether the effect of antenatal corticosteroids (ANS) differs in male and female fetuses without anomalies born before 32 weeks in terms of mortality and short-term morbidity.

METHODS:

This single-center retrospective study included infants born before 32 weeks' gestation and admitted to the neonatal intensive care unit between January 1, 2018, and December 31, 2020.

RESULTS:

The study included 210 infants with a median gestational age of 28.6 weeks (24-31.6), a birth weight of 1065 g (445-2165), and an ANS use rate of 80%. Compared to female fetuses exposed to ANS, male fetuses exposed to ANS had a lower mortality rate (23% and 11%, respectively, p = 0.038), but there were no differences in intraventricular hemorrhage, retinopathy of prematurity, necrotizing enterocolitis, respiratory distress syndrome, and APGAR scores of 1st and 5th but an increased rate of bronchopulmonary dysplasia (moderate/severe) (p = 0.008). In addition, the mortality rate was similar in exposed and unexposed female fetuses (p = 0.850). Enzyme activities and steroid levels in the placenta might be different in male and female fetuses, which could explain the results of ANS administration.

CONCLUSIONS:

In our study, we have shown that ANS has no effect on mortality in female fetuses younger than 32 weeks. Future studies may focus on adjusting the administration of ANS based on fetal sex, altering the dose or taking fetal sex into account when performing ANS.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Obstet Gynaecol Res Asunto de la revista: GINECOLOGIA / OBSTETRICIA Año: 2024 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Australia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Obstet Gynaecol Res Asunto de la revista: GINECOLOGIA / OBSTETRICIA Año: 2024 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Australia